Intra-Cellular Therapies Inc. (ITCI) Breaks into New 52-Week High on February 05 Session

Equities Staff  |

Shares of Intra-Cellular Therapies Inc. (ITCI) broke into a new 52-week high yesterday, hitting a peak of $35.84. Shares closed at $35.76 after opening at $35.04 for a move of 2.71%. The company now has a market cap of $2.87 billion.

Investors and traders can learn a lot about a stock’s momentum when it sets a new 52-week high. As an example, bullish investors view a company hitting its highest price in a year as a sign of momentum and may interpret it as a signal to buy. On the other hand, bearish investors could view a new 52-week high as a signal of the end of a strong run, with the stock possibly peaking out before an impending period of decline.

For Intra-Cellular Therapies Inc., the new 52-week high came on volume of 693,927. The stock has a float of 80.16 million shares and average daily volume of $n/a. It has a 50-day SMA of $n/a and a 200-day SMA of $n/a.

For a complete fundamental analysis analysis of Intra-Cellular Therapies Inc., check out Equities.com’s Stock Valuation Analysis report for ITCI.

Still paying commissions on stock trades? Equities.com now offers $7.99/month unlimited trading and flat-fee options trading for $89.99/month! Get started today by https://www.equities.com/trading-start

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Intra-Cellular Therapies Inc. is based out of New York, and has some 330 employees. Its CEO is Sharon Mates.

Intra-Cellular Therapies Inc. is also a component of the Russell 2000 Index, which is an invaluable tool for any small-cap investor. Consisting of the smaller 2,000 publicly traded companies of the 3,000 largest companies in America by market cap (which combine to make the broader Russell 3000 index), the Russell 2000 gives the most comprehensive snapshot of the small-cap market of any index out there.

What's more, the Russell 2000 is maintained by Russell Investments, a company committed to using rules-based methodologies to construct unbiased indices that differ from the committee-selected Dow Jones Industrial Average or S&P 500.

To get more information on Intra-Cellular Therapies Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: ITCI’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Is AI Ready for Prime Time: Jeff Kagan
Stocks Close Broadly Lower as Powell Signals Faster Tapering by Fed
UK Regulator Rules Facebook Must Sell Giphy
US Bank Profits Slip 1.2% in Q3
Omicron Variant Reached Europe Earlier Than Previously Thought
Vaccine Stocks Soar Amid Omicron-Related Volatility
Former Trump Chief of Staff Mark Meadows To Cooperate With House Panel Investigating Jan. 6 Insurrection
Jerome Powell Says Fed To Discuss Accelerated Tapering of Bond Purchases at Next Policy Meeting



Market Movers

Sponsored Financial Content